A number of other research firms have also issued reports on GSK. Jefferies Financial Group raised GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Morgan Stanley assumed coverage on GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, GSK currently has an average rating of “Moderate Buy”.
GSK Price Performance
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its stake in GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 676 shares during the last quarter. Fairfield Bush & CO. acquired a new stake in GSK during the 2nd quarter worth approximately $28,000. Larson Financial Group LLC lifted its position in GSK by 271.8% during the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 647 shares during the period. BKM Wealth Management LLC acquired a new stake in shares of GSK in the 4th quarter valued at approximately $32,000. Finally, SRS Capital Advisors Inc. boosted its stake in shares of GSK by 52.9% in the first quarter. SRS Capital Advisors Inc. now owns 1,090 shares of the pharmaceutical company’s stock valued at $39,000 after buying an additional 377 shares in the last quarter. Hedge funds and other institutional investors own 13.53% of the company’s stock.
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Five stocks we like better than GSK
- What Investors Need to Know to Beat the Market
- CF Industries stock leaves competitors in the dust
- How to invest in marijuana stocks in 7 steps
- Salesforce and MongoDB: 2 must-own tech stocks
- Investing In Preferred Stock vs. Common Stock
- Udemy stock got boosted by analysts, massive growth at discounts
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.